Insider Transactions Reported by 17 Insiders of Pelthos Therapeutics Inc.

Symbol
PTHS on NYSE
Location
Durham, NC

Insiders trading volume in the past year

Pelthos Therapeutics Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Todd C. Davis Director $15,259,315 02 Jul 2025
LIGAND PHARMACEUTICALS INC Director, 10%+ Owner $15,000,000 17 Dec 2025
Ezra M. Friedberg Director $4,482,195 -$280,281 -5.9% 25 Nov 2025
Motif Pharmaceuticals Ltd. 10%+ Owner $442,434 15 Feb 2024
Boswell Prayer Ltd. 10%+ Owner $432,301 15 Feb 2024
Aperture Healthcare Ventures Ltd. 10%+ Owner $400,972 15 Feb 2024
Andrew J. Einhorn Director $342,000 23 Dec 2025
AME Equities LLC 10%+ Owner $330,093 15 Feb 2024
Richard Malamut Director $199,116 02 Jul 2025
Francis Knuettel II CFO, Treas & Secty $117,173 02 Jul 2025
Matthew Pauls Director $37,246 10 Dec 2025
Richard B. Baxter Director 02 Jul 2025
Sai Rangarao Chief Commercial Officer 02 Jul 2025
Scott M. Plesha CEO and President, Director 02 Jul 2025
Peter S. Greenleaf Director 02 Jul 2025
Chia-Lin Simmons Director 11 Apr 2025
Eric Lang Chief Medical Officer 14 Jun 2024

Recent Insider Transactions by Companies or Individuals for Pelthos Therapeutics Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Andrew J. Einhorn CHRO Common Stock Award 12,000 12,000 23 Dec 2025 Direct
Ligand Pharmaceuticals Inc CHRO Senior Secured Convertible Note Award 0 $9,000,000 17 Dec 2025 Direct
Ligand Pharmaceuticals Inc CHRO Senior Secured Convertible Note Disposed to Issuer 0 0 17 Dec 2025 Direct
Matthew Pauls CHRO Common Stock Gift -89.9% -9,542 1,074 10 Dec 2025 Direct
Ezra M. Friedberg CHRO Common Stock Sale -25% $280,280 $28.03 -10,000 30,000 25 Nov 2025 By Balmoral Financial Group LLC
Ligand Pharmaceuticals Inc CHRO Senior Secured Convertible Note Award 0 $9,000,000 06 Nov 2025 Direct
Matthew Pauls CHRO Common Stock Options Exercise 25% 2,123 10,616 02 Oct 2025 Direct
Matthew Pauls CHRO Restricted Stock Units Options Exercise -12.5% -2,123 14,862 02 Oct 2025 Direct
Matthew Pauls CHRO Common Stock Options Exercise 8,493 8,493 02 Jul 2025 Direct
Matthew Pauls CHRO Restricted Stock Units Options Exercise -33.3% -8,493 16,985 02 Jul 2025 Direct
Scott M. Plesha CHRO Stock Option Award 255,000 255,000 02 Jul 2025 Direct
Scott M. Plesha CHRO Restricted Stock Units Award 83,678 83,678 02 Jul 2025 Direct
Sai Rangarao CHRO Stock Option Award 93,000 93,000 02 Jul 2025 Direct
Sai Rangarao CHRO Restricted Stock Units Award 30,518 30,518 02 Jul 2025 Direct
Richard B. Baxter CHRO Stock Option Award 58,230 58,230 02 Jul 2025 Direct
Richard B. Baxter CHRO Restricted Stock Units Award 19,108 19,108 02 Jul 2025 Direct
Peter Greenleaf CHRO Stock Option Award 77,640 77,640 02 Jul 2025 Direct
Peter Greenleaf CHRO Restricted Stock Units Award 25,478 25,478 02 Jul 2025 Direct
Matthew Pauls CHRO Stock Option Award 77,640 77,640 02 Jul 2025 Direct
Matthew Pauls CHRO Restricted Stock Units Award 25,478 25,478 02 Jul 2025 Direct
Francis Knuettel II CHRO Stock Option Award 236.8% 102,000 145,074 02 Jul 2025 Direct
Francis Knuettel II CHRO Restricted Stock Units Award 33,472 33,472 02 Jul 2025 Direct
Todd C. Davis CHRO Stock Option Award 58,230 58,230 02 Jul 2025 Direct
Todd C. Davis CHRO Restricted Stock Units Award 107% 19,108 36,969 02 Jul 2025 Direct
Ezra M. Friedberg CHRO Stock Option Award 58,230 58,230 02 Jul 2025 Direct
Ezra M. Friedberg CHRO Restricted Stock Units Award 214.6% 19,108 28,012 02 Jul 2025 Direct
Richard Malamut CHRO Stock Option Award 58,230 58,230 02 Jul 2025 Direct
Richard Malamut CHRO Restricted Stock Units Award 214.6% 19,108 28,012 02 Jul 2025 Direct
Ezra M. Friedberg CHRO Common Stock Conversion of derivative security 40,000 40,000 01 Jul 2025 By Key Recovery Group LLC
Ezra M. Friedberg CHRO Common Stock Conversion of derivative security 40,000 40,000 01 Jul 2025 By Balmoral Financial Group LLC
Ezra M. Friedberg CHRO Series A Convertible Preferred Stock Conversion of derivative security -100% -40,000 0 01 Jul 2025 By Key Recovery Group LLC
Ezra M. Friedberg CHRO Series A Convertible Preferred Stock Conversion of derivative security -100% -40,000 0 01 Jul 2025 By Balmoral Financial Group LLC
Ezra M. Friedberg CHRO Series A Convertible Preferred Stock Purchase 40,000 40,000 01 Jul 2025 By Key Recovery Group LLC
Ezra M. Friedberg CHRO Series A Convertible Preferred Stock Purchase 40,000 40,000 01 Jul 2025 By Balmoral Financial Group LLC
Francis Knuettel II CHRO Common Stock Conversion of derivative security 10,000 10,000 01 Jul 2025 By Camden Capital LLC
Francis Knuettel II CHRO Series A Convertible Preferred Stock Conversion of derivative security -100% -10,000 0 01 Jul 2025 See footnote
Francis Knuettel II CHRO Series A Convertible Preferred Stock Other 10,000 10,000 01 Jul 2025 See footnote
Todd C. Davis CHRO Common Stock Conversion of derivative security 1,500,000 1,500,000 01 Jul 2025 By Ligand Pharmaceuticals Incorporated
Todd C. Davis CHRO Series A Convertible Preferred Stock Other 1.01% 31,279 3,127,868 01 Jul 2025 See footnote
Todd C. Davis CHRO Series A Convertible Preferred Stock Conversion of derivative security -83.3% -15,000 3,000 01 Jul 2025 See footnote
Ligand Pharmaceuticals Inc CHRO Common Stock Conversion of derivative security 1,500,000 1,500,000 01 Jul 2025 Direct
Ligand Pharmaceuticals Inc CHRO Series A Convertible Preferred Stock Other 1042.6% 31,279 34,279 01 Jul 2025 Direct
Ligand Pharmaceuticals Inc CHRO Series A Convertible Preferred Stock Conversion of derivative security -83.3% -15,000 3,000 01 Jul 2025 Direct
Chia-Lin Simmons CHRO Stock Option Award 23.8% 25,000 130,000 11 Apr 2025 Direct
Francis Knuettel II CHRO Stock Option Award 14.3% 53,988 430,736 11 Apr 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.